Page last updated: 2024-11-13
cluvenone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cluvenone: an antineoplastic agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71719494 |
| CHEMBL ID | 2336601 |
| MeSH ID | M0555099 |
Synonyms (2)
| Synonym |
|---|
| CHEMBL2336601 |
| cluvenone |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID730929 | Partition coefficient, log D of the compound at pH 7.4 | 2013 | Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1 | Garcinia xanthones as orally active antitumor agents. |
| AID730930 | Cytotoxicity against human U251 cells assessed as cell viability after 24 hrs by MTT assay | 2013 | Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1 | Garcinia xanthones as orally active antitumor agents. |
| AID730927 | Permeability of the compound at pH 7.4 by PAMPA | 2013 | Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1 | Garcinia xanthones as orally active antitumor agents. |
| AID730931 | Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay | 2013 | Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1 | Garcinia xanthones as orally active antitumor agents. |
| AID730928 | Intrinsic solubility of the compound | 2013 | Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1 | Garcinia xanthones as orally active antitumor agents. |
| AID730932 | Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay | 2013 | Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1 | Garcinia xanthones as orally active antitumor agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 13.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.28) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||